Kenvue Inc. (NYSE:KVUE) Given Average Rating of "Hold" by Brokerages

Key Points

• Kenvue Inc. has received a consensus recommendation of "Hold" from twelve brokerages, with one analyst rating it a sell, seven holding, and four buying the stock.
• The average 12-month target price for Kenvue's stock is $23.32, reflecting recent adjustments from various firms including Evercore ISI and Canaccord Genuity Group.
• Kenvue reported a quarterly EPS of $0.29, surpassing expectations, while its quarterly revenue of $3.84 billion fell short of the predicted $3.94 billion.

Kenvue Inc. (NYSE:KVUE - Get Free Report) has earned a consensus recommendation of "Hold" from the twelve brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $23.3182.

Several brokerages recently commented on KVUE. Zacks Research raised Kenvue to a "strong sell" rating in a research report on Monday, August 11th. Evercore ISI cut their price objective on Kenvue from $23.00 to $18.00 and set an "in-line" rating for the company in a research report on Tuesday. Canaccord Genuity Group cut their price objective on Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Barclays cut their price objective on Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Tuesday, July 15th. Finally, JPMorgan Chase & Co. cut their price objective on Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, July 25th.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $16.20 on Friday. The stock has a 50 day moving average price of $20.48 and a 200 day moving average price of $21.88. Kenvue has a 52 week low of $16.14 and a 52 week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The stock has a market capitalization of $31.09 billion, a PE ratio of 21.89, a price-to-earnings-growth ratio of 2.42 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion during the quarter, compared to analysts' expectations of $3.94 billion. During the same period in the prior year, the firm posted $0.32 earnings per share. The business's quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.1%. Kenvue's payout ratio is 112.16%.

Institutional Trading of Kenvue

A number of hedge funds have recently made changes to their positions in the business. Pittenger & Anderson Inc. bought a new position in shares of Kenvue during the first quarter worth approximately $30,000. TruNorth Capital Management LLC bought a new position in shares of Kenvue during the first quarter worth approximately $36,000. Truvestments Capital LLC bought a new position in shares of Kenvue during the first quarter worth approximately $37,000. Trust Co. of Vermont increased its stake in shares of Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock worth $33,000 after purchasing an additional 1,150 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Kenvue by 378.5% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after purchasing an additional 1,287 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.